pNAT and CYP2D6 gene polymorphism in epileptic patients
- 1 November 1994
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 48 (9) , 1717-1720
- https://doi.org/10.1016/0006-2952(94)90456-1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- PCR-based CYP2D6 genotyping for Finnish lung cancer patientsPharmacogenetics, 1993
- Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteersEuropean Journal of Clinical Pharmacology, 1992
- Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's diseaseThe Lancet, 1992
- Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibilityCarcinogenesis: Integrative Cancer Research, 1992
- Mutant debrisoquine hydroxylation genes in Parkinson's diseaseThe Lancet, 1992
- Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles ofCYP2D6in a European PopulationDNA and Cell Biology, 1991
- N-acetyltransferase polymorphism: Comparison of phenotype and genotype in humansBiochemical Pharmacology, 1991
- [15] Genetic analysis of cytochrome P450 systemPublished by Elsevier ,1991
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990